AstuteAnalytica India Pvt. Ltd. <\/p>\n
Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.<\/p>\n
Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) — The global radiopharmaceuticals market<\/a> was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025\u20132033.<\/p>\n<\/p>\n The radiopharmaceuticals market is experiencing a tidal wave of strategic investment, signaling immense confidence from major industry players. Mega-mergers are rapidly consolidating the landscape as pharmaceutical giants acquire specialized expertise and promising late-stage assets.<\/p>\n Bristol-Myers Squibb committed to a landmark $4.1 billion acquisition of RayzeBio for its actinium-based pipeline.<\/p>\n AstraZeneca fortified its position with a $2 billion acquisition of Fusion Pharmaceuticals, while Eli Lilly made a decisive entry through a $1.4 billion deal to acquire Point Biopharma.<\/p>\n Request Sample Pages: https:\/\/www.astuteanalytica.com\/request-sample\/radiopharmaceuticals-market<\/a><\/p>\n Not to be outdone, radiopharmaceuticals market leader Novartis expanded its formidable portfolio by acquiring Mariana Oncology for $1 billion upfront. The Novartis-Mariana deal also includes a significant $750 million in potential milestone payments, underscoring the perceived value. Further demonstrating the trend, Lantheus Holdings agreed to acquire Evergreen Theragnostics, a deal involving a $250 million upfront payment and up to an additional $752.5 million in performance-based milestones.<\/p>\n Venture capital in the radiopharmaceuticals market is simultaneously fueling a new generation of innovators, enabling emerging companies to accelerate their research and development efforts. In a major 2024 funding round,<\/p>\n German biotech ITM Radiopharma secured an impressive $205 million to advance its pioneering cancer treatment research.<\/p>\n AdvanCell completed an oversubscribed Series C financing round, raising a substantial $112 million. Radiopharm Theranostics received commitments from key investors to raise $70 million for its development programs.<\/p>\n Nucleus RadioPharma successfully closed an oversubscribed Series A funding round of $56 million.<\/p>\n Radionetics Oncology completed a fundraising effort for $52.5 million to push its pipeline forward.<\/p>\n Meanwhile, Ratio Therapeutics raised $50 million to finance the launch of clinical trials for its solid tumor candidates<\/p>\n United Theranostics closed a $15 million senior debt facility to expand its nationwide network, showcasing broad investor enthusiasm across the sector.<\/p>\n Key Findings in Radiopharmaceuticals Market<\/p>\n Market Forecast (2033)<\/p>\n US$ 13.4 billion<\/p>\n CAGR<\/p>\n 7.8%<\/p>\n Largest Region (2024)<\/p>\n North America (45%)<\/p>\n By Radioisotope <\/p>\n Technetium 99m (42%)<\/p>\n By Type<\/p>\n Diagnostic (70%)<\/p>\n By Application <\/p>\n Cancer (53%)<\/p>\n By End Users<\/p>\n Hospitals and clinics (52%)<\/p>\n Top Drivers<\/p>\n Increasing prevalence of cancer and cardiac diseases boosts product demand.<\/p>\n Technological advancements in nuclear imaging and AI enhance treatment precision.<\/p>\n Major pharma investments and acquisitions are accelerating market expansion rapidly.<\/p>\n Top Trends<\/p>\n The rapid emergence of theranostics is driving personalized medicine approaches.<\/p>\n A growing research and development focus on targeted alpha therapies.<\/p>\n Expansion into emerging markets and new applications beyond oncology.<\/p>\n Top Challenges<\/p>\n Complex regulatory hurdles and manufacturing bottlenecks limit market access.<\/p>\n Logistical challenges due to the short half-life of radioisotopes.<\/p>\n High treatment costs and inconsistent reimbursement policies hinder patient access.<\/p>\n Blockbuster Sales and High-Value Licensing Deals Affirm Strong Commercial Viability<\/p>\n The commercial success of products in the radiopharmaceuticals market highlights their immense market demand. Novartis\u2019s Pluvicto generated blockbuster sales of $1.04 billion in just the first nine months of 2024. Meanwhile, Lantheus\u2019s diagnostic imaging agent Pylarify was projected to surpass $1 billion in sales by year-end 2024, emphasizing the importance of both therapeutic and diagnostic radiopharmaceuticals. Additionally, the well-established isotope Technetium-99m remains critical, utilized in over 40 million diagnostic procedures annually, which forms a substantial foundation for future market growth.<\/p>\n High-value licensing and collaboration deals further confirm the long-term commercial promise of these therapies across the global radiopharmaceuticals market. Eli Lilly\u2019s strategic agreement with Aktis Oncology has a potential value of $1.1 billion, signaling confidence in next-generation radiotherapies. In 2024, Sanofi\u2019s $100 million licensing deal with RadioMedix and Orano Med targets innovative neuroendocrine tumor treatments. Eli Lilly initiated its partnership with Aktis with a $60 million upfront payment focused on solid tumor pipelines, while Lantheus\u2019s $3 million licensing deal for two experimental assets from Radiopharm Theranostics reflects ongoing vibrant innovation and collaboration across large and smaller entities.<\/p>\n Aggressive Infrastructure Expansion Prepares Industry for Unprecedented Production Demand Growth<\/p>\n To meet surging demand, companies \u00a0in the radiopharmaceuticals market are heavily investing in manufacturing and distribution capacity expansions. NorthStar Medical Radioisotopes is constructing a 52,000-square-foot commercial-scale radioisotope production facility, critical for supply chain stability. Ionetix is expanding its Michigan manufacturing site by over 5,000 square feet, adding a second cyclotron with dual target stations to boost isotope output. These enhancements are pivotal for reliable production of existing and novel isotopes powering market growth.<\/p>\n Distribution infrastructures are also ramping to ensure timely patient access to these sensitive therapies. Jubilant Radiopharma runs a national network of 43 SPECT radiopharmacies and 3 PET manufacturing facilities. Novartis activated its fourth global manufacturing site in early 2024 to support Pluvicto\u2019s robust demand. Additionally, Minerva Imaging in Denmark received its first commercial production module for Astatine-211, advancing new alpha-emitter therapies.<\/p>\n A Vibrant and Advancing Clinical Pipeline Signals a Wave of Innovation<\/p>\n The radiopharmaceuticals market\u2019s promising future is backed by a robust clinical development pipeline. By early 2025, 34 active Phase 3 trials were underway to evaluate novel therapies. These late-stage studies, including the RaRe study on bone metastases treatment options, demonstrate a maturing and rapidly evolving field.<\/p>\n Pipeline diversity is notable, with over 30 companies developing theranostic pairs combining diagnostics and therapeutics. The Phase 3 SIERRA trial\u2019s outcome for Acute Myeloid Leukemia, expected in 2025, could revolutionize hematologic cancer treatments. Bristol Myers Squibb\u2019s RYZ101, acquired with RayzeBio, is in advanced trials targeting neuroendocrine tumors. Eli Lilly, strengthened by its acquisition of Point Biopharma, is progressing Lu-177-based candidates through Phase 3 studies, promising impactful new therapies.<\/p>\n Favorable US Regulatory and Reimbursement Changes Pave Way for Radiopharmaceuticals Market Access<\/p>\n The U.S. regulatory environment increasingly favors radiopharmaceutical innovation and market entry. CMS finalized a November 2024 rule adjusting reimbursement for diagnostic agents, instituting a $630 per day cost threshold that encourages the development of advanced imaging products. Starting January 2026, a $10 per dose add-on will be implemented for therapies using domestically produced Technetium-99m, bolstering the supply chain.<\/p>\n The FDA released draft guidance in August 2025 to optimize dosage design in oncology radiopharmaceutical trials, facilitating clearer development pathways for the radiopharmaceuticals market. The Nuclear Regulatory Commission\u2019s August 2024 information notice addressed safety improvements following review of medical events from 2021-2023. Further regulatory clarity is expected with the Office of Inspector General\u2019s update to Advisory Opinion No. 21-13, anticipated in February 2025.<\/p>\n Proactive International Regulatory Actions Secure Global Supply Chains and Patient Access<\/p>\n Globally, regulatory agencies are advancing strategies to stabilize radiopharmaceuticals market supply and access. The European Medicines Agency issued strategic recommendations in April 2025 to address supply chain vulnerabilities. Since 2024, all European Union member states uniformly regulate radiopharmaceuticals, including hospital-prepared products, ensuring consistent quality and safety standards.<\/p>\n Infrastructure projects such as the Netherlands\u2019 PALLAS research reactor under construction are critical for European isotope production. Broader market access is supported by pan-national initiatives like Canada\u2019s Pharma Alliance including Novartis\u2019s Pluvicto in public health plans, expanding patient reach. Collaborative efforts continue under the European Radioisotope Valley Initiative, upgrading production and fostering cross-border cooperation. Expansion plans by companies like Best Cyclotron Systems into Europe and India, plus strategic transatlantic partnerships such as ITM\u2019s joint facility with Canada\u2019s Nuclear Laboratories, underscore vibrant global growth.<\/p>\n Breakthroughs in Isotope Production Technology Unleash Next-Generation Therapeutic Potential<\/p>\n Innovations in isotope production underpin the growth of next-gen alpha and beta therapies in the radiopharmaceuticals market. In 2024, TerraPower secured sufficient Thorium-229 supplies to support commercial-scale Actinium-225 production, enabled by IsoTek\u2019s extraction of over 15 grams of this rare element at Oak Ridge National Laboratory, overcoming prior constraints.<\/p>\n Canada\u2019s Darlington Nuclear Generating Station became the world\u2019s first commercial power reactor to produce Molybdenum-99, a vital diagnostic isotope, marking a milestone in supply reliability. This facility is also preparing to produce Yttrium-90, an essential therapeutic isotope. Kinectrics launched Ytterbium-176 production, precursor to Lutetium-177, and plans to add Gadolinium-160 to its portfolio, enhancing therapy options. Ontario\u2019s $6.8 million funding to McMaster Nuclear Reactor further strengthens domestic isotope production for research and patient care.<\/p>\n Escalating Global Cancer Burden Fundamentally Drives Long-Term Market Expansion<\/p>\n The vast and growing global cancer burden underlies the radiopharmaceuticals market\u2019s expansion. April 2024 data estimates 20 million new cancer cases worldwide occurred in 2022, with 9.7 million deaths attributable to the disease. This glaring unmet need emphasizes demand for precise, targeted therapies like radiopharmaceuticals that deliver radiation directly to cancer cells, minimizing collateral damage.<\/p>\n The cancer challenge intensifies, with projections of 29.9 million new cases and 15.3 million deaths annually by 2040. Cancer now accounts for nearly 1 in every 6 global deaths, driving investments in innovative treatments. Pediatric approvals, such as 2024 FDA\u2019s greenlight for Tovorafenib in low-grade glioma patients as young as six months, indicate widening treatment scope. Longstanding standards like radioactive iodine (I-131) therapy underscore persistent therapeutic roles.<\/p>\n Established Leaders and Agile Newcomers Intensify Therapeutic Oncology Competition<\/p>\n The competitive landscape features pharmaceutical giants and agile newcomers driving innovation. Novartis leads, with two blockbuster therapeutics, Pluvicto and Lutathera, setting high commercial benchmarks. Bayer AG holds a strong position with its alpha-emitter Xofigo, widely used for prostate cancer bone metastases. GE HealthCare reinforced its commitment by acquiring full ownership of Nihon Medi-Physics, a major radiopharmaceutical manufacturer.<\/p>\n Other major players include Cardinal Health, leveraging extensive distribution and product offerings to ensure market reach; Curium Pharma, spanning comprehensive diagnostic and therapeutic products; Telix Pharmaceuticals, rapidly growing with a pipeline of molecularly targeted radiation agents challenging incumbents; and Jubilant Pharmova, contributing to global industry diversity and competitiveness.<\/p>\n Looking for Country-Level or Section-Wise Data? Customize This Report: https:\/\/www.astuteanalytica.com\/ask-for-customization\/radiopharmaceuticals-market<\/a><\/p>\n Top Companies in the Radiopharmaceuticals Market<\/p>\n Market Segmentation Overview<\/p>\n By Type<\/p>\n By Radioisotope<\/p>\n Iodine I<\/p>\n Gallium 68<\/p>\n Technetium 99m<\/p>\n Fluorine 18<\/p>\n Others<\/p>\n By Application<\/p>\n By End User<\/p>\n Hospitals and clinics<\/p>\n Medical Imaging centers<\/p>\n Others<\/p>\n By Region<\/p>\n North America<\/p>\n Europe<\/p>\n Western Europe<\/p>\n The UK<\/p>\n Germany<\/p>\n France<\/p>\n Italy<\/p>\n Spain<\/p>\n Rest of Western Europe<\/p>\n Eastern Europe<\/p>\n Poland<\/p>\n Russia<\/p>\n Rest of Eastern Europe<\/p>\n Asia Pacific<\/p>\n Middle East and Africa<\/p>\n Saudi Arabia<\/p>\n South Africa<\/p>\n UAE<\/p>\n Rest of MEA<\/p>\n South America<\/p>\n Argentina<\/p>\n Brazil<\/p>\n Rest of South America<\/p>\n Need a Detailed Walkthrough of the Report? Request a Live Session: https:\/\/www.astuteanalytica.com\/report-walkthrough\/radiopharmaceuticals-market<\/a><\/p>\n About Astute Analytica<\/p>\n Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.<\/p>\n With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.<\/p>\n Contact Us: CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries:\u00a0sales@astuteanalytica.com Website: https:\/\/www.astuteanalytica.com\/<\/p>\n
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries:\u00a0sales@astuteanalytica.com<\/a>
Website: https:\/\/www.astuteanalytica.com\/<\/a>
Follow us on: LinkedIn\u00a0<\/a>|\u00a0Twitter\u00a0<\/a>|\u00a0YouTube<\/a><\/p>\n